← Back
Vaxcyte
PCVX · listed on Nasdaq · worth $9.55 billion
$60.67
+1.17% on Oct 27
No insider bought Vaxcyte stock in the last year. They sold it 41 times, $7.55 million in all. One member of Congress reported trading Vaxcyte in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
137.1M shares
87% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, five insiders sold Vaxcyte stock and none bought. 16 of the 41 sales are marked on the filing as planned in advance; all by company executives. The biggest seller was Grant Pickering, CHIEF EXECUTIVE OFFICER.
Planned sales
Form 144 notices filed for Vaxcyte in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Elvia Cowan filed to sell 19,000 shares on 5 Oct; no sale reported yet10b5-1 plan adopted 8 Dec 2025 · Notice on SEC.gov
COO Jim Wassil filed to sell 18,000 shares on 5 Oct; no sale reported yet10b5-1 plan adopted 9 Dec 2025 · Notice on SEC.gov
COO Jim Wassil filed to sell 2,250 shares on 1 Oct; sold 2,250 by 1 Oct10b5-1 plan adopted 9 Dec 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Vaxcyte, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateJanus Henderson Group12.1%Aug 11Reported stake, oldest first: 0.1% (Aug 7) → 12.1% (Aug 11)Crossed 10%
Filed by someone who owns 5% or more and does not plan to influence the company. · updateJanus Henderson Group0.1%Aug 7
Each history starts at the oldest report we hold.
US Congress
Members of Congress who reported trading Vaxcyte in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Vaxcyte.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 2SoldJim WassilOct 2 · Traded Oct 1 · EVP, Chief Scientific Ofc, COO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.95 @ $57.09$5.4K
Oct 2SoldJim WassilOct 2 · Traded Oct 1 · EVP, Chief Scientific Ofc, COO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,155 @ $56.65$122.1K
36 more with Pro →Analysts, earnings and news
Analysts' price target
$109.00 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
0 of 4 quarters above
Q1 '26−$2.30 a share−$0.53
Q4 '25−$1.80 a share−$0.30
Q3 '25−$1.56 a share−$0.32
Q2 '25−$1.22 a share−$0.06